Protein palmitoylation and cardiovascular disease

Home > Archive>Volume 31, Issue 8, 2023 >645-653

Protein palmitoylation and cardiovascular disease
DOI:
                        
                    
CSTR:
                        [cstr]
                    
Author:
                        FAN SisiFAN Sisi
Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
WANG LiwenWANG Liwen
Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LI QinLI Qin
Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LI LanfangLI Lanfang
Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
JIANG ZhishengJIANG Zhisheng
Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Institute of Pharmacy and Pharmacology, University of South China & Institute of Cardiovascular Disease, University of South China & Key Laboratory for Arteriosclerology of Hunan Province & International Laboratory for Scientific Innovation and Co-operation of Hunan Province, Hengyang, Hunan 421001, China)
Clc Number:R5
Fund Project:

Article

Figures

Metrics

Reference [33]

Cited by

Materials

Comments

Abstract:

Protein palmitoylation is a kind of post-translational lipid modification of proteins that widely exists in organisms. Generally, S-palmitoylation occurs mainly through the covalent attachment of palmitic acid to protein-specific cysteine residues via labile thioester linkages. S-palmitoylation is usually reversible because the thioester bond will be hydrolyzed under certain conditions, causing protein depalmitoylation. In addition, S-palmitoylation is closely associated with the occurrence and development of many cardiovascular diseases. This review summarizes the process of protein palmitoylation and depalmitoylation, the relationship between protein palmitoylation and cardiovascular diseases, including arrhythmia, atherosclerosis, pulmonary hypertension, heart failure, and thrombotic diseases, which provide a new direction for cardiovascular disease treatment.

Key words:protein palmitoylation; protein acyltransferase; acyl protein thioesterase; palmitoyl protein thioesterase; cardiovascular disease

Reference

[1] 丁玉娇, 韩颖颖, 周婧雯.棕榈酰化蛋白及蛋白质的棕榈酰化研究进展.亚热带植物科学, 8,7(4):395-403.DING Y J, HAN Y Y, ZHOU J W.Progress in research of palmitoylated proteins and protein palmitoylation.Subtr Plant Sci, 8,7(4):395-403.

[2] WANG Y T, LU H J, FANG C Y, et al.Palmitoylation as a signal for delivery.Adv Exp Med Biol, 0,8:399-424.

[3] KO P J, DIXON S J.Protein palmitoylation and cancer.EMBO Rep, 8,9(10):e46666.

[4] JIN J Y, ZHI X L, WANG X H, et al.Protein palmitoylation and its pathophysiological relevance.J Cell Physiol, 1,6(5):3220-3233.

[5] DAS T, YOUNT J S, HANG H C.Protein S-palmitoylation in immunity.Open Biol, 1,1(3):200411.

[6] ZMUDA F, CHAMBERLAIN L H.Regulatory effects of post-translational modifications on zDHHC S-acyltransferases.J Biol Chem, 0,5(43):14640-14652.

[7] MALGAPO M I P, LINDER M E.Substrate recruitment by zDHHC protein acyltransferases.Open Biol, 1,1(4):210026.

[8] LEMONIDIS K, SALAUN C, KOUSKOU M, et al.Substrate selectivity in the zDHHC family of S-acyltransferases.Biochem Soc Trans, 7,5(3):751-758.

[9] SALAUN C, LOCATELLI C, ZMUDA F, et al.Accessory proteins of the zDHHC family of S-acylation enzymes.J Cell Sci, 0,3(22):jcs251819.

[10] ZHOU B H, HAO Q Y, LIANG Y M, et al.Protein palmitoylation in cancer:molecular functions and therapeutic potential.Mol Oncol, 3,7(1):3-26.

[11] ZEIDMAN R, JACKSON C S, MAGEE A I.Protein acyl thioesterases (Review).Mol Membr Biol, 9,6(1):32-41.

[12] 孙慧慧.APT1去棕榈酰化CD36影响其质膜定位.厦门:厦门大学, 2019:1-85.SUN H H.Depalmitoylation of CD36 by APT1 affects its plasma membrane localization.Xiamen:Xiamen University, 2019:1-85.

[13] KOSTER K P, YOSHII A.Depalmitoylation by palmitoyl-protein thioesterase 1 in neuronal health and degeneration.Front Synaptic Neurosci, 9,1:25.

[14] CALERO G, GUPTA P, NONATO M C, et al.The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2.J Biol Chem, 3,8(39):37957-37964.

[15] LIN D T, CONIBEAR E.ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization.Elife, 5,4:e11306.

[16] WON S J, CHEUNG SEE KIT M, MARTIN B R.Protein depalmitoylases.Crit Rev Biochem Mol Biol, 8,3(1):83-98.

[17] 王思敏, 燕银芳, 纪玉强.蛋白质N-糖基化在心血管疾病中的研究进展.中国动脉硬化杂志, 3,1(1):1-12.WANG S M, YAN Y F, JI Y Q.Research progress of protein N-glycosylation in cardiovascular diseases.Chin J Arterioscler, 3,1(1):1-12.

[18] 李涛, 曾晓荣.钠钙交换体与心脏疾病的研究进展.泸州医学院学报, 4,7(1):65-68.LI T, ZENG X R.Research progress on sodium-calcium exchangers and heart diseases.J Luzhou Med Coll, 4,7(1):65-68.

[19] 宿俊杰, 齐戈尧, 党晓智, 等.钠钙交换体的生理和病理生理功能研究进展.生理学报, 4,6(2):241-251.SU J J, QI G Y, DANG X Z, et al.Research progress on the physiological and pathophysiological functions of sodium-calcium exchangers.Acta Physiol Sin, 4,6(2):241-251.

[20] 林晨晖, 李源, 王焱.心肌细胞钠钙交换体研究进展.实用心脑肺血管病杂志, 1,9(1):145-148.LIN C H, LI Y, WANG Y.Research progress on cardiomyocyte sodium-calcium exchanger.Pract J Cardiac Cereb Pneum Vasc Dis, 1,9(1):145-148.

[21] REILLY L, HOWIE J, WYPIJEWSKI K, et al.Palmitoylation of the Na/Ca exchanger cytoplasmic loop controls its inactivation and internalization during stress signaling.FASEB J, 5,9(11):4532-4543.

[22] PLAIN F, CONGREVE S D, YEE R S Z, et al.An amphipathic α-helix directs palmitoylation of the large intracellular loop of the sodium/calcium exchanger.J Biol Chem, 7,2(25):10745-10752.

[23] GK C, PLAIN F, ROBERTSON A D, et al.Dynamic palmitoylation of the sodium-calcium exchanger modulates its structure, affinity for lipid-ordered domains, and inhibition by XIP.Cell Rep, 0,1(10):107697.

[24] BORREGO J, FEHER A, JOST N, et al.Peptide inhibitors of Kv1.5:an option for the treatment of atrial fibrillation.Pharmaceuticals (Basel), 1,4(12):1303.

[25] GUO X, CHEN W, SUN H, et al.Kv1.5 inhibitors for treatment of atrial fibrillation:a tradeoff between selectivity and non-selectivity.Curr Top Med Chem, 6,6(16):1843-1854.

[26] RAJARATINAM H, MOKHTAR N F, ASMA-ABDULLAH N, et al.Discovering the triad between Nav1.5, breast cancer, and the immune system:a fundamental review and future perspectives.Biomolecules, 2,2(2):310.

[27] PEI Z F, XIAO Y C, MENG J W, et al.Cardiac sodium channel palmitoylation regulates channel availability and myocyte excitability with implications for arrhythmia generation.Nat Commun, 6,7:12035.

[28] 肖素军, 赵明.动脉粥样硬化与免疫.中国动脉硬化杂志, 2,0(4):277-286.XIAO S J, ZHAO M.Atherosclerosis and immunity.Chin J Arterioscler, 2,0(4):277-286.

[29] 石茗西, 江丽萍, 陈金智, 等.动脉粥样硬化中巨噬细胞表型调控的研究进展.中国动脉硬化杂志, 2,0(4):364-368.SHI M X, JIANG L P, CHEN J Z, et al.Progress in the regulation of macrophage phenotype in atherosclerosis.Chin J Arterioscler, 2,0(4):364-368.

[30] SHU H Y, PENG Y Z, HANG W J, et al.The role of CD36 in cardiovascular disease.Cardiovasc Res, 2,8(1):115-129.

[31] WANG J, HAO J W, WANG X, et al.DHHC4 and DHHC5 facilitate fatty acid uptake by palmitoylating and targeting CD36 to the plasma membrane.Cell Rep, 9,6(1):209-221.e5.

[32] MEILER S, BAUMER Y, HUANG Z, et al.Selenoprotein K is required for palmitoylation of CD36 in macrophages:implications in foam cell formation and atherogenesis.J Leukoc Biol, 3,3(5):771-780.

[33] HUMBERT M, KOVACS G, HOEPER M M, et al.2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.Eur Respir J, 3,1(1):2200879.

Get Citation

FAN Sisi, WANG Liwen, LI Qin, LI Lanfang, JIANG Zhisheng. Protein palmitoylation and cardiovascular disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(8):645-653.

Copy

Article Metrics

Abstract:761
PDF: 1131
HTML: 0
Cited by: 0

History

Received:February 08,2023
Revised:April 24,2023
Adopted:
Online: July 20,2023
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code